QuidelOrtho Corporation QDEL is showing resilience in its core diagnostics businesses, but the investment case remains constrained by worsening visibility in China, uncertain respiratory demand and financial pressure. The mix leaves investors weighing operational progress against risks that could limit earnings recovery.
Cost savings and product investment provide support, yet weaker cash conversion and elevated leverage keep the near-term risk-reward profile unfavorable.
QDEL’s Core Growth Offers Some Support
Second-quarter revenues outside China grew 6% at constant currency, reflecting healthier trends across much of QuidelOrtho’s portfolio. Labs revenues outside China increased 9%, while Immunohematology revenues outside China rose 5%.
Management expects those two core businesses outside China to grow roughly 3%-5% in aggregate during the second half of 2026. Their recurring-revenue characteristics provide some stability while other parts of the business remain more volatile.
Image Source: Zacks Investment Research
China Weakness Clouds QDEL’s Near-Term Visibility
China revenues fell 18.7% on a reported basis and 23.3% at constant currency in the second quarter. Slower distributor purchases ahead of evolving national in-vitro diagnostics pricing guidelines weighed on demand, particularly in Labs.
Customers also reduced inventories more quickly than management had anticipated after quarter-end. With final pricing rules and implementation timing still uncertain, QuidelOrtho expects China-related challenges to persist through the remainder of 2026.
QDEL’s Cost Actions Help but Margins Stay Pressured
Adjusted EBITDA increased 21% year over year to $129 million in the second quarter, showing that productivity and expense-control efforts are having an impact. The Optimization Plan continues to target approximately $50 million of net cost savings through 2027.
That progress has not removed margin pressure. Adjusted gross margin contracted 130 basis points to 44.4%, with lower China volumes contributing to an unfavorable geographic mix. Further cost execution remains important if revenue headwinds persist.
NULEXA Gives QDEL a Longer-Term Growth Option
QuidelOrtho is shifting its molecular strategy toward NULEXA following the April acquisition of LEX Diagnostics. The company is advancing manufacturing scale-up, supply-chain readiness and commercial launch preparations, with customer placements and test utilization expected to build as the 2026-2027 respiratory season progresses.
NULEXA also provides a platform for future menu expansion, but adoption is not assured. Competition remains substantial. Abbott Laboratories ABT reported $3.1 billion in second-quarter Diagnostics sales, while Danaher Corporation DHR reported 7% Diagnostics sales growth, highlighting the scale of established diagnostics rivals.
QDEL’s Leverage and Cash Use Keep Risk Elevated
QuidelOrtho ended the second quarter with $123.4 million in cash and cash equivalents against $2.89 billion of total debt. During the first six months of 2026, operating activities used $143.6 million of cash compared with cash generation in the prior-year period.
Weak cash conversion increases the importance of delivering on cost savings and improving working-capital efficiency. Elevated leverage also leaves less room for execution setbacks if China weakness or softer respiratory demand lasts longer than expected.
QDEL’s Bearish Signal Supports a Cautious View
QDEL’s core growth, cost actions and NULEXA opportunity provide reasons to monitor the stock, but they do not yet outweigh the company’s weaker earnings visibility, margin pressure and balance-sheet risks. The investment case remains better suited to a cautious stance until operating improvements translate into stronger cash performance.
The stock currently carries a Zacks Rank #5 (Strong Sell). QDEL also has a Value Score of B, but its Growth Score of F and Momentum Score of F signal weak growth and momentum characteristics, while the VGM Score of D points to an unfavorable combined profile. Given that Style Scores are designed to complement the Zacks Rank, the current mix does not provide a strong signal for buying the shares despite the relatively favorable value reading.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.